Comparison · NCT01667081-983ffd54
GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced an Event of Clinical Interest (ECI) During the Long-Term Follow-Up
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced an Event of Clinical Interest (ECI) During the Long-Term Follow-Up. Trial comparisons, record NCT01667081-983ffd54. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01667081-983ffd54
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0513 | 0.0423 | 0.0622 | wilson | |
| Risk in group 2 | 0.0076 | 0.00296 | 0.0194 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0437 | 0.0289 | 0.0555 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 6.75 | 2.5 | 18.3 | log | |
| Odds ratio, group 1 over group 2 | 7.06 | 2.59 | 19.3 | log | |
| Number needed to treat, for one more participant with the outcome on GZR 100 mg + EBR 50 mg +/- RBV than on Other GZR Regimen | 22.9 | 18 | 34.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GZR 100 mg + EBR 50 mg +/- RBV | Participants previously received GZR 100mg +EBR 50mg with or without RBV in a prior study. | 98 | 1,909 | OG000 |
| Group 2 | Other GZR Regimen | Participants previously received at least one dose of GZR in a prior study | 4 | 526 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Experienced an Event of Clinical Interest (ECI) During the Long-Term Follow-Up
- Description
An ECI includes spontaneous bacterial peritonitis, variceal bleeding, ascites, encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, liver transplant, cardiovascular disease limited to angina and myocardial infarction, neurologic disorders limited to transient ischemic attack (TIA) or stroke, graft rejection in participants who have undergone liver or kidney transplant, or one of the following in participants from the MK-5172-052 (NCT02092350) base study: kidney transplant, decreased estimated glomerular filtration rate (eGFR), new onset diabetes, cryoglobulinemia, or post transplantation glomerulonephritis.
- Time frame
- Up to ~60 months after enrollment in this study
- Population
All participants treated with GZR in a prior study. Three participants were excluded from analysis; two participants enrolled in error failed to receive at least one dose of GZR in a prior study (each received a comparator regimen in a prior base study) and one participant had insufficient long-term follow-up data (participant withdrew consent on Day 27).
Source ClinicalTrials.gov
Trial
- Title
- Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
- NCT number
- NCT01667081
- Phases
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2022-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01667081?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01667081-983ffd54